Acute myelogenous leukemia in two patients treated with azathioprine for nonmalignant diseases.
D000328:Adult; D001379:Azathioprine / Q000009:adverse effects* / Q000627:therapeutic use; D001772:Blood Cell Count; D001792:Blood Platelets / Q000473:pathology; D001853:Bone Marrow / Q000473:pathology; D001854:Bone Marrow Cells; D003561:Cytarabine / Q000627:therapeutic use; D003630:Daunorubicin / Q000627:therapeutic use; D006084:Graft Rejection; D006505:Hepatitis / Q000188:drug therapy; D006801:Humans; D007165:Immunosuppression Therapy / Q000009:adverse effects; D016030:Kidney Transplantation; D015470:Leukemia, Myeloid, Acute / Q000139:chemically induced* / Q000175:diagnosis / Q000188:drug therapy; D007958:Leukocyte Count; D008297:Male; D011241:Prednisone / Q000009:adverse effects* / Q000627:therapeutic use; D013866:Thioguanine / Q000627:therapeutic use; D014184:Transplantation, Homologous
D003561:Cytarabine; D013866:Thioguanine; D001379:Azathioprine; D011241:Prednisone; D003630:Daunorubicin